Shots:

• Lexicon to receive $260M as termination fee including $208M upon signing the termination agreement and $52M is payable within 12mos. Lexicon regain global rights to develop & commercialize Zynquista for T1D & T2D and coordinate with Sanofi in the transition of ongoing clinical studies and other activities
• In Jul’2019- Sanofi has terminated its 4yrs. partnership following the disappointing results of three P-III studies of Zynquista- which is being developed as an add-on to insulin for diabetic patients
• Zynquista is an oral dual inhibitor of SGLT1 and SGLT2- approved as an adjunct to insulin therapy to improve glycemic control in T1D patients in Europe. Lexicon is planning to file regulatory approval in the US & EU for T2D with the expected ongoing P-III study results demonstrating CV & renal benefits

Click here to­ read full press release/ article | Ref: lexicon| Image: Chicago Tribune